Compare THRY & EMBC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | THRY | EMBC |
|---|---|---|
| Founded | 2012 | 1924 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Industrial Machinery/Components | Medical/Dental Instruments |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 179.6M | 199.9M |
| IPO Year | 2020 | 2021 |
| Metric | THRY | EMBC |
|---|---|---|
| Price | $2.44 | $4.42 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 4 | 2 |
| Target Price | $9.33 | ★ $18.50 |
| AVG Volume (30 Days) | 639.3K | ★ 1.2M |
| Earning Date | 04-30-2026 | 05-05-2026 |
| Dividend Yield | N/A | ★ 6.88% |
| EPS Growth | ★ 100.50 | 20.90 |
| EPS | N/A | ★ 0.67 |
| Revenue | ★ $785,015,000.00 | N/A |
| Revenue This Year | N/A | $1.17 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | $5.22 |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $1.91 | $2.77 |
| 52 Week High | $13.94 | $15.55 |
| Indicator | THRY | EMBC |
|---|---|---|
| Relative Strength Index (RSI) | 26.62 | 50.44 |
| Support Level | $1.91 | $3.07 |
| Resistance Level | $4.15 | $9.45 |
| Average True Range (ATR) | 0.32 | 0.16 |
| MACD | -0.18 | 0.03 |
| Stochastic Oscillator | 5.90 | 43.48 |
Thryv Holdings Inc is dedicated to supporting local, independent service-based businesses and emerging franchises by providing a cloud-based software platform, and marketing solutions to entrepreneurs. The group are provider of SaaS all-in-one small business management software in addition to providing print and digital marketing solutions to SMBs. Its solutions enable small and medium-sized business clients to attract and generate new business leads, manage their customer relationships efficiently with artificial intelligence (AI) tools and automation. The group has two business segments; Thryv SaaS deriving maximum revenue and Thryv Marketing Services.
Embecta Corp is a medical device company focused on providing solutions to improve the health and well-being of people living with diabetes. It has a broad portfolio of marketed products, including various pen needles, syringes, and safety devices, which are complemented by a proprietary digital application designed to assist people with managing their diabetes. The company predominantly sells products to wholesalers and distributors that sell to retail and institutional channels who in turn sell to patients or use the products to deliver insulin injections to patients. It also provides contract manufacturing services. Geographically, the company derives a majority of its revenue from the United States.